Skip to main content
. Author manuscript; available in PMC: 2021 May 9.
Published in final edited form as: Cell Rep. 2021 Apr 13;35(2):108998. doi: 10.1016/j.celrep.2021.108998

Figure 2. Endogenous GSDME permits IL-1β release with limited secondary pyroptosis.

Figure 2.

(A and B) PMA-differentiated (100 ng/mL, 16 h) wild-type, GSDMD−/−, and GSDMD−/−GSDME−/− THP-1 cells treated with nigericin (20 μM) assessed for propidium iodide uptake, cell lysis through supernatant lactate dehydrogenase activity assay (A), and cell morphology by microscopy (B).

(C and D) Immunoblots of these cells treated with nigericin or S. typhimurium (MOI = 10).

(E) Mature IL-1β ELISA for supernatants of wild-type and indicated gasdermin knockout differentiated THP-1 treated with nigericin (20 μM).

Immunoblots are representative of at least five independent experiments. Scale bar, 50 μm. Graph bars represent mean ± standard error of biological replicates. Graph points represent pooled technical replicates per biological replicate.

See also Figure S2.